Now showing items 1-2 of 2
miR-17 in imatinib resistance and response to tyrosine kinase inhibitors in chronic myeloid leukemia cells
(Zerbinis Medical Publications, 2013-04)
In this study we examined the expression levels of miR-17 which possesses oncogenic activities through downregulation of CDKN1A, p21 and E2F1 tumor suppressor genes, in imatinib sensitive and resistant chronic myeloid ...
Mechanisms responsible for nilotinib resistance in human chronic myeloid leukemia cells and reversal of resistance
(Taylor & Francis, 2013-06)
Multidrug resistance remains a significant obstacle to successful chemotherapy. The ability to determine the possible resistance mechanisms and surmount the resistance is likely to improve chemotherapy. Nilotinib is a very ...